Drug Profile
Research programme: anticancer vaccine - CureTech
Alternative Names: CT-201Latest Information Update: 15 Sep 2011
Price :
$50
*
At a glance
- Originator CureTech
- Class Cancer vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Aug 2007 Preclinical development is ongoing
- 11 Jun 2005 Preclinical trials in Cancer in Israel (Injection)